A comment window is now open on how the FDA wants robotically-assisted surgical systems brought to market. Draft guidance published Sept. 24 lays out the evidence packages makers should assemble.
The draft spans laboratory work, human data and what goes on the label. These are teleoperated systems that help qualified practitioners position and control one or more instruments during open, minimally invasive or endoluminal procedures. Comments close Nov. 24 ahead of a final version.
Why the category needed a map
Robotic surgery has become one of medtech’s fastest-moving segments, and the intelligence inside those systems keeps growing. Motion scaling, sensing and image guidance now blend into models that assist a surgeon’s hands, which makes a device look less like hardware and more like a computing platform that happens to move.
The draft lands as clearances accumulate. Medtronic recently won FDA clearance to bring its LigaSure vessel-sealing line onto the Hugo robotic system, an early example of a major instrument maker extending a familiar tool onto a robotic arm.
A predictable submission path is a commercial question, not just a clinical one. Companies planning multi-year robotic programs need to know which evidence the agency will weigh, because trial design choices made early are costly to revisit.
With the November deadline, commenting before the guidance finalizes is the industry’s only lever.
